Compare Huntington Ingalls Industries Inc (HII) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Ingalls Industries Inc vs Recursion Pharmaceuticals Inc — how do they compare? Huntington Ingalls Industries Inc trades at $264.76 (market cap $10.44B), while Recursion Pharmaceuticals Inc trades at $4.33 (market cap $2.14B). The key difference: Huntington Ingalls Industries Inc is far larger — about 4.9× Recursion Pharmaceuticals Inc's market cap, and Huntington Ingalls Industries Inc pays a 2.08% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Ingalls Industries Inc for 28 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| HII | RXRX | |
|---|---|---|
Market Cap | $10.44B | $2.14B |
Volume | 440,462 | 30,789,535 |
Sector | Industrials | Health |
52-Week High | $453.73 | $6.79 |
52-Week Low | $257.05 | $2.84 |
Typical Hold Time | 28 Days | 23 Days |
Enterprise Value | $13.37B | $1.66B |
Dividend Yield | 2.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HII trades at $264.51, up 1.47% with a bearish technical signal despite recent earnings beats. The company shows solid fundamentals with a $12.48B revenue, 5.01% net margin, and attractive valuation (P/E 15.78, P/S 0.79). Recent contract wins including a $5.1B aircraft carrier overhaul and 10 unmanned vessel orders provide strong revenue visibility. Analyst consensus is mixed with 40.7% buy ratings but a $363.67 price target suggesting 37% upside potential.
The stock presents value opportunity with strong defense sector positioning and $57.3B backlog, though technical weakness and execution risks on major contracts warrant caution. Upside catalysts include continued earnings beats and contract execution, while risks involve defense budget uncertainty and project delays. Current levels offer entry point for long-term investors given the significant discount to analyst targets.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
